KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony zaawansowany nowotwór litý (badanie mikroskopowe)
- •Nowotwory z mutacjami HRAS, KRAS, NRAS lub ich wzmocnieniem
- •Wcześniejsze leczenie standardowe, które nie zadziałało lub przestało działać
- •Dla części pacjentów: wcześniejsze leczenie immunoterapią
- •Dla grupy z rakiem nerki: maksymalnie 3 wcześniejsze leczenia przeciwrakowe
- •Mierzalne ogniska nowotworu widoczne w badaniach obrazowych
- •Pacjenci, którzy nigdy nie stosowali leku cabozantinib
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 14, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (38)
Mayo Clinic Comprehensive Cancer Center
Phoenix, United States
University of Arizona
Tucson, United States
University of Southern California
Los Angeles, United States
Cedars-Sinai Medical Center
Los Angeles, United States
UCLA Department of Medicine
Los Angeles, United States
Sarah Cannon Research Institute at HealthONE
Denver, United States
AdventHealth Celebration
Celebration, United States
Mayo Clinic Comprehensive Cancer Center
Jacksonville, United States
Florida Cancer Specialists
Sarasota, United States
University of Iowa Hospitals & Clinics
Iowa City, United States
Dana-Farber Cancer Institute
Boston, United States
Henry Ford Health System
Detroit, United States
Mayo Clinic Comprehensive Cancer Center
Rochester, United States
Washington University School of Medicine
St Louis, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, United States
Ohio State University
Columbus, United States
OU Stephenson Cancer Center
Oklahoma City, United States
UPMC Hillman Cancer Center
Pittsburgh, United States
SCRI - Oncology Partners
Nashville, United States
UT Southwestern Simmons Cancer Center
Dallas, United States
MD Anderson Cancer Center
Houston, United States
University of Wisconsin (Carbone Cancer Center)
Madison, United States
Centre Leon Berard
Lyon, France
Oncologie médicale - Pitié-Salpêtrière
Paris, France
Hopital Européen Georges Pompidou
Paris, France
Institut Universitaire du Cancer Toulouse - Oncopole
Toulouse, France
Charité - Universitätsmedizin Berlin
Berlin, Germany
Universitätsklinikum Ulm
Ulm, Germany
Universitätsklinikum Würzburg
Würzburg, Germany
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS
Bologna, Italy
Fondazione Piemonte per l'Oncologia - IRCCs Candiolo
Candiolo, Italy
Istituto Nazionale Tumori IRCCS
Naples, Italy
Humanitas University
Rozzano, Italy
AOU Verona - Centro Ricerche Cliniche di Verona
Verona, Italy
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital de la Santa Creu i de Sant Pau
Barcelona, Spain
Hospital HM Sanchinarro START Madrid-CIOCC
Madrid, Spain
Hospital Universitario Virgen del Rocío
Seville, Spain
Trial contact
Kura Medical Information
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.